← Back to Search

18F-FDG PET Scan for Cardiovascular Disease

Phase < 1
Recruiting
Led By Guobao Wang, PhD
Research Sponsored by University of California, Davis
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up during the procedure
Awards & highlights
No Placebo-Only Group

Summary

This trial uses a special imaging technique to take pictures of blood flow and sugar use in patients with heart disease, cancer, and brain disorders. This helps doctors see how well blood is flowing and how much sugar different parts of the body are using. This imaging tool is primarily used for diagnosing and evaluating cancer by measuring glucose metabolism.

Who is the study for?
This trial is for adults over 18 who can consent and follow the study schedule. Healthy volunteers must have no cardiovascular or metabolic diseases, while patients with such conditions can join. Exclusions include high blood glucose, weight over 240 kg, pregnancy, recent PET scans in other studies, prisoners, and those unable to consent.
What is being tested?
The trial aims to develop a PET imaging method using a single tracer (18F-FDG) to assess both blood flow and glucose metabolism simultaneously. This could potentially streamline the process of diagnosing various conditions related to heart and metabolic health.
What are the potential side effects?
Potential side effects may include reactions from the injection site due to tracer administration or discomfort from lying still during scanning. Anxiety or claustrophobia might occur due to enclosed space of the scanner.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~during the procedure
This trial's timeline: 3 weeks for screening, Varies for treatment, and during the procedure for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Blood Flow
Secondary study objectives
Metabolism change when using Butanol
Metabolism change when using FDG

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Experimental: PET/CT scansExperimental Treatment2 Interventions
Each subject will undergo a dynamic 18F-FDG PET/CT scan and a dynamic 11C-butanol PET/CT scan on the EXPLORER total-body PET/CT system
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
18F-FDG
2017
Completed Phase 4
~750

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
18F-fluorodeoxyglucose (FDG) PET imaging works by using FDG, a glucose analog, to measure glucose metabolism in tissues. This imaging technique is particularly useful for identifying areas of high metabolic activity, such as cancer cells. Tracer kinetic modeling in FDG PET allows for the simultaneous assessment of blood flow and glucose metabolism, offering a comprehensive view of tissue function. For healthy subjects, this is important as it aids in the early detection of abnormalities, monitoring metabolic changes, and assessing treatment efficacy non-invasively.
STatistically Assigned Response Criteria in Solid Tumors (STARCIST).Assessment of <sup>10</sup>B concentration in boron neutron capture therapy: potential of image-guided therapy using <sup>18</sup>FBPA PET.Absolute quantification of [(11)C]docetaxel kinetics in lung cancer patients using positron emission tomography.

Find a Location

Who is running the clinical trial?

University of California, DavisLead Sponsor
944 Previous Clinical Trials
4,755,980 Total Patients Enrolled
National Institute for Biomedical Imaging and Bioengineering (NIBIB)NIH
93 Previous Clinical Trials
20,232 Total Patients Enrolled
Guobao Wang, PhDPrincipal InvestigatorUniversity of California, Davis
3 Previous Clinical Trials
36 Total Patients Enrolled
~40 spots leftby Aug 2028